Table 1.

Compound	Type	Study site	Patient	Usage	Subject number (placebo vs experiment)	Dosage	Trial duration (weeks)	Clinical outcomes	Clinical ratings	Reference
Glycine	OL	US	SZ	Add on	11 (no placebo)	5-25 (g/day)	32-36	-	Neuroleptics intake	(78)
	OL	US	SZ	Add on	6 (no placebo)	10.8 (g/day)	0.6-8	-	BPRS, SANS, CGI, SAS, AIMS	(79)
	OL	US	SZ	Add on	6 (no placebo)	15 (g/day)	6	-	BPRS	(80)
	DB + additional OL	US	SZ	Add on	7 vs 7	2-30 (g/day)	8 DB + 8 OL	+ (Negative symptoms)	PANSS, ESRS, AIMS	(83)
	OL	US	SZ	Add on	5 (no placebo)	0.14-0.8 (g/kg/day)	8	+ (Negative symptoms)	PANSS, SANS, ESRS, AIMS	(88)
	DB (Crossover)	Israel	TRS SZ	Add on	11 vs 11	0.8 (g/kg/day)	6	+ (Negative, depressive, cognitive symptoms)	PANSS, SAS, AIMS	(70)
	DB (Crossover)	Israel	TRS SZ	Add on	22 vs 22	0.8 (g/kg/day)	6	+ (Negative, depressive, cognitive symptoms)	BPRS, PANSS, SAS, AIMS	(84)
	DB (Parallel)	US	TRS SZ	Add on (Clozapine)	10 vs 9	30 (g/day)	12	-	BPRS, SANS, SAS, SAFTEE	(90)
	DB (Parallel)	US	SZ	Add on (Clozapine)	13 vs 14	60 (g/day)	2 SB + 8 DB	-	BPRS, PNASS, SANS, HDRS, SAS, GAS,	(91)
	DB (Crossover)	US	SZ	Add on	6 vs 6	0.2-0.8 (g/kg/day)	6	+ (Negative symptoms)	PANSS, BARS, SAS, AIMS	(85)
	DB (Crossover)	Israel	SZ	Add on (Olanzapine & risperidone)	17 vs 17 (Olanzapine: 12; Risperidone: 5)	0.06-0.8 (g/kg/day)	6	+ (Negative, cognitive, positive symptoms, excitement, depression)	BPRS, PANSS, SAS, AIMS	(86)
	DB (Crossover)	Canada	TRS SZ	Add on (Clozapine)	12 vs 12	60 (g/day)	28	-	BPRS, PANSS, GAF, ESRS	(92)
	DB (Parallel) (NCT00222235)	US & Israel	SZ or SZA	Add on (Without cloazpine)	45 (55) vs 42 (54)	15-60 (g/day)	16	-	BPRS, SANS, CGI, SAS, AIMS	(93)
	DB (Parallel)	Australia	SZ or SZA	Add on	21 vs 22 (SZ:17; SZA:5)	0.2-0.6 (g/kg/day)	6	+ (Acute: duration MMN; chronic:PANSS scores)	PANSS, CDRS, WSAS, ERP (MMN)	(87)
	DB (Crossover)	US	SZ (9p24.1 CNV)	Add on	2 vs 2	6-48 (g/day)	6	+ (Clinical symptoms)	BPRS, PANSS, CGI, Motor abnormalities	(89)
	OL				2 (no placebo)	5.4-86.5 (g/day)	47	+ (Clinical symptoms)		

Abbreviations: +: Positive clinical results; -: Negative clinical results; AIMS: Abnormal Involuntary Movements Scale; BPRS: Brief Psychiatric Rating Scale; CDRS: Calgary Depression Rating Scale; CGI: Clinical Global Impression; DB: double-blind; ERP: Event Related Potential; ESRS: Extrapyramidal Symptom Rating Scale; GAF: Global Assessment of Functioning Scale; GAS: Global Assessment Scale; HDRS: Hamilton Depression Rating Scale; MMN: Mismatch negativity; OL: open-label; PANSS: Positive and Negative Syndrome Scale; SAFTEE: Systematic Assessment for Treatment Emergent Event; SANS: Scale for the Assessment of Negative Symptoms; SAS: Simpson Angus Scale for Assessment of Extrapyramidal Side Effects; SZ: schizophrenia; SZA: schizoaffective disorder; TRS: treatment-resistant; WSAS: Work and Social Adjustment Scale